X4 Pharmaceuticals, Inc — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
X4 Pharmaceuticals held a virtual investor day on October 29, 2026, presenting updates on mavorixafor, an oral CXCR4 antagonist in development for primary chronic neutropenia (PCN). The pivotal Phase 3 4WARD trial (N=126 patients) expects full enrollment by Q4 2026 with topline data in Q1 2028 and potential FDA approval in late 2028/early 2029. A planned Phase 2b 4STEPS trial (~25 patients across ~25 U.S. and U.K. sites) will evaluate G-CSF dose reduction, with initiation in Q1 2027 and data in H1 2028. Market research identifies a base case of ~15,000 symptomatic PCN patients aged 12+ with 2+ infections annually and ANC ≤1,000 cells/µL.
Why this rating
Investor presentation is routine disclosure; no new material agreements, financing, or clinical results. Company ($14.9M market cap) announcing expected timelines already public; cash runway extends into 2029 but no new capital raised disclosed here.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.